EMR · NYSE
| FY2025 | FY2024 | FY2023 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $18.02B | $17.49B | $15.16B | $1.66B | $13.80B | $12.93B | $16.79B | $18.37B |
| Cost of Revenue | $8.50B | $8.61B | $7.74B | — | $7.50B | $7.20B | $9.78B | $10.56B |
| Gross Profit | $9.52B | $8.88B | $7.43B | — | $6.31B | $7.56B | $7.01B | $7.82B |
| Research & Development | $771.00M | $781.00M | $523.00M | — | $385.00M | $347.00M | $439.00M | $454.00M |
| Selling, General & Administrative | $5.10B | $5.14B | $4.19B | — | $3.61B | $3.49B | $3.99B | $4.46B |
| Interest Expense | — | — | — | — | — | $147.00M | — | — |
| Other Income / (Expense) | $81.00M | $72.00M | $145.00M | — | $100.00M | $71.00M | $12.00M | $8.00M |
| Income Before Taxes | $2.93B | $2.02B | $2.90B | — | $2.43B | $1.76B | $2.33B | $2.86B |
| Provision for Income Taxes | $696.00M | $415.00M | $642.00M | — | $549.00M | $346.00M | $345.00M | $531.00M |
| Net Income | $2.29B | $1.97B | $13.22B | — | $3.23B | $2.30B | $1.97B | $2.31B |
| Basic EPS | $4.06 | $3.44 | $23.00 | — | $5.44 | $3.85 | $3.26 | $3.74 |
| Diluted EPS | $4.04 | $3.43 | $22.88 | — | $5.41 | $3.82 | $3.24 | $3.71 |
| Basic Shares Outstanding | 564.00M | 571.30M | 574.20M | — | 592.90M | 598.10M | 602.90M | 616.20M |
| Diluted Shares Outstanding | 566.70M | 574.00M | 577.30M | — | 596.30M | 601.80M | 606.60M | 620.60M |
| Period | Consensus EPS | Low | High | Estimates | Revisions |
|---|---|---|---|---|---|
| Sep 2026 | $6.49 | $6.43 | $6.54 | 9 | ↑0 ↓1 |
| Sep 2027 | $7.14 | $6.88 | $7.30 | 10 | ↑0 ↓1 |
| Sep 2028 | $7.47 | $7.47 | $7.47 | 1 | ↑0 ↓0 |
